24/7 Market News Snapshot 03 September, 2025 – ProMIS Neurosciences Inc. Common Shares (ON) (NASDAQ:PMN)

September 3, 2025

DENVER, Colo., 03 September, 2025 (www.247marketnews.com) – (NASDAQ:PMN) are discussed in this article.
ProMIS Neurosciences Inc. is currently experiencing significant market momentum, with shares trading at $0.699, reflecting an impressive increase of over 30% from the previous close of $0.537 in pre-market activity. This surge is accompanied by a robust trading volume of 10.09 million shares, signaling heightened investor interest and confidence in the company’s innovative strategies for combating neurodegenerative diseases. Observers are encouraged to monitor the situation closely as this bullish trend could indicate the beginning of a more substantial rally for ProMIS.

In a critical advancement for the company, ProMIS has received unanimous approval from the independent Data and Safety Monitoring Board (DSMB) to proceed with Cohort 3 in its PRECISE-AD Phase 1b clinical trial. This pivotal phase will assess PMN310, an innovative monoclonal antibody aimed at selectively targeting toxic amyloid-beta oligomers while sparing amyloid plaque. With the completion of enrollment for Cohort 2, the ongoing trial is on track to enroll a total of 128 patients, with anticipated interim data available by the second quarter of 2026 and final results expected in the fourth quarter of the same year.

Neil Warma, President and CEO of ProMIS, expressed enthusiasm about the progression to Cohort 3, highlighting the encouraging safety profile of PMN310. He stated, “The favorable safety profile we have observed thus far positions PMN310 as a distinct therapeutic option, aimed at mitigating the risks associated with traditional amyloid-targeting therapies.” The trial is not only set to evaluate safety but will also include a comprehensive analysis of biomarkers linked to neuronal injury, further enhancing the understanding of PMN310’s therapeutic potential.

As ProMIS prepares to showcase its latest advancements at the H.C. Wainwright 27th Annual Global Investment Conference, the company remains committed to addressing the pressing unmet needs within the Alzheimer’s disease treatment landscape, reinforcing its role as a frontrunner in advancing solutions for neurodegenerative disorders.

Related news for (PMN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.